Year one on a GLP-1 has a scoreboard: the number goes down. Year two has no scoreboard. The weight has plateaued — as it eventually must — and the patient faces a question the prescription label doesn't answer: what does success look like now?
Key Takeaways
- Plateau is the intended destination of therapy, not a failure state — but patients experience it as loss of progress.
- Maintenance decisions in year two: hold dose, step down to a lower maintenance dose, or structured discontinuation.
- Cost fatigue is the most common real-world reason for year-two dropout — and 2026 pricing has changed that math substantially.
- The patients who navigate year two best redefine the goal from 'losing' to 'defending' a weight range.
The Psychology of the Plateau
Around months 9–15, weight loss slows and stops for most patients. Physiologically this is expected: energy expenditure falls as mass falls, and the drug's effect reaches equilibrium against the new baseline. But psychologically, patients who were motivated by weekly losses suddenly feel the medication "stopped working." It didn't — it's now doing the harder, invisible job of holding the line against regain.
The Three Year-Two Paths
Hold the full dose
Simplest clinically, most expensive historically. Right for patients whose appetite remains strong at lower doses or who have diabetes indications.
Step down to a maintenance dose
The increasingly standard play: reduce to the lowest dose that keeps hunger manageable and weight stable — often 0.5–1.0mg semaglutide-equivalent. Clinical experience through 2026 suggests a large fraction of patients hold their loss at doses far below their titration peak.
Structured discontinuation
Full stop with a taper, a monitoring plan, and a pre-agreed restart trigger. Honest framing from the data: regain risk is real, and this path demands the strongest habit foundation.
The Cost-Fatigue Factor
Surveys and clinic experience agree: the most common reason patients quit in year two isn't side effects or dissatisfaction — it's paying month after month for a number that no longer moves. This is where 2026's price war matters. Maintenance at $49–$179/month is a fundamentally different proposition than maintenance at $500+:
Telos Rx — Semaglutide
Compounded semaglutide — from $49/mo on 12-month plans
Same flat-at-every-dose structure on the semaglutide side: $199 month-to-month, $129 quarterly, $99 semi-annual, $49/mo annual.
Compounded medications are not FDA-approved.
Visit Telos Rx Paid linkGala
Injectable — $179/mo flat, every dose
One flat price at every dose level, which removes the dose-increase billing surprise entirely.
Compounded medications are not FDA-approved.
Visit Gala Paid linkWellorithm
Oral tablets — sema $147/mo, tirz $249/mo
Among the lowest published oral compounded prices we track, with tablet formats for both semaglutide and tirzepatide.
Compounded medications are not FDA-approved.
Visit Wellorithm Paid linkRedefining the Scoreboard
The clinicians who keep patients successful in year two replace the weight-loss scoreboard with a defense scoreboard: staying within a 5-pound range, maintaining lean mass on DEXA or even a home scale's trend, keeping A1C and lipids at their improved levels. Maintenance isn't the absence of progress. It's the entire point — and it deserves a plan, a dose, and a budget designed for the long game.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.